Topic
3 claims checked
Claim:
Many CRISPR-based sickle cell disease clinical trials primarily edit the BCL11A gene or its enhancer to reactivate fetal hemoglobin rather than directly repairing the HBB mutation.
NOT BS
Claim:
The 2021 Frangoul et al. report on CTX001 stated that the sickle cell disease patient had increased fetal hemoglobin and experienced no severe pain crises during approximately 16.6 months of follow-up.
NOT BS
Claim:
Hydroxyurea treatment for sickle cell disease increases fetal hemoglobin production and reduces red blood cell sickling.
NOT BS